Fiasp FDA Approval History
Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Fiasp is a newer formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of initial insulin absorption.
Development Timeline for Fiasp
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.